Teladoc Health (TDOC) Missed On Earnings And Guided Lower, Is The Discount Too Wide?

Why Teladoc Health’s latest earnings matter for investors

Teladoc Health (TDOC) set the tone for the stock this week after reporting quarterly results that showed a 4% revenue decline, missed forecasts on profitability, and softer guidance for the coming quarter.

The update pointed to a 9.2% average drop in customer spending in recent years even as user counts grew. Management signaled expectations for another period of lower revenue and negative earnings per share.

Recent trading suggests pressure on Teladoc Health’s momentum is building. The stock’s 7 day share price return of 2.27% contrasts with a 90 day share price decline of 21.93%, while the 5 year total shareholder return is down 95.33%, which underscores how much sentiment has reset around the story.

Scan 37 healthcare AI stocks to see which digital health players investors are rotating toward as Teladoc Health works through weaker revenue trends and cautious guidance.

Teladoc Health’s share slide raises a blunt question. Are investors finally catching up to a weaker revenue story, or has sentiment swung harder than the fundamentals justify as valuations reset from here?

Most Popular Narrative: 58% Undervalued

On the latest numbers, Teladoc Health closed at $6.30 while the most followed narrative pegs fair value closer to $15. That gap has turned the stock into a battleground between investors focused on past drawdowns and those zeroing in on cash generation and balance sheet strength.

Despite the market narrative of a failing pandemic stock, Teladoc’s underlying financial engine tells a radically different story.

Teladoc is a cash-generative healthcare utility with $750M+ in hard cash protecting the downside, between $130M and $170M in annual free cash flow, and an expanding insurance-reimbursed mental health model.

See why 3 investors see Teladoc Health as 58% undervalued.

Result: Fair Value of $15 (UNDERVALUED)

Still, the Teladoc Health story breaks quickly if BetterHelp’s insurance shift stalls or if telehealth rivals pull users away faster than expected.

Find out about the key risks to this Teladoc Health narrative.

Next Steps

Sentiment around Teladoc Health is clearly split, so consider this a prompt to act promptly, review both sides of the story, and weigh 3 key rewards and 2 important warning signs

Looking for more ideas beyond Teladoc Health?

If Teladoc Health has sharpened your focus on risk, reward, and valuation, do not stop here. Use the screener to hunt for stronger setups now.

• Target potential mispricings by scanning companies that combine quality fundamentals with attractive entry points through the 33 high quality undervalued stocks.
• Prioritise resilience by zeroing in on businesses with robust financial footing using the list of solid balance sheet and fundamentals (23 results).
• Spot tomorrow’s leaders early by filtering for underfollowed opportunities through the 16 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com